Dr Verena Brucklacher-Waldert

Verena is a Principal Scientist at Horizon Discovery Ltd, based in Cambridge, UK. Horizon Discovery is a world leader in the utilization of gene editing and gene modulation technologies to support the greater understanding of gene function, the genetic drivers behind human disease and the development of molecular cell and gene therapies for precision medicine. The company’s products and services are used by thousands of scientists working in academic institutes, pharmaceutical companies and clinical diagnostic laboratories around the globe. Verena received her doctorate in Neuroimmunology from the University of Tübingen, Germany, and gained a postdoctoral research fellowship from the German Research Foundation that enabled her to intensify her studies on T cell biology in Marc Veldhoen's lab in Cambridge, UK. Before Verena joined Horizon Discovery she developed assays for hit identification and lead characterisation of multifunctional, oncology-relevant antibody-fragments for the biopharmaceutical company Crescendo Biologics. At Horizon Discovery she is providing high level scientific expertise and technical leadership for new and ongoing activities within the Immunology services team.